JP2020522555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522555A5 JP2020522555A5 JP2019567709A JP2019567709A JP2020522555A5 JP 2020522555 A5 JP2020522555 A5 JP 2020522555A5 JP 2019567709 A JP2019567709 A JP 2019567709A JP 2019567709 A JP2019567709 A JP 2019567709A JP 2020522555 A5 JP2020522555 A5 JP 2020522555A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- icos
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 104
- 102000036639 antigens Human genes 0.000 claims description 104
- 108091007433 antigens Proteins 0.000 claims description 104
- 239000012634 fragment Substances 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010061818 Disease progression Diseases 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 description 21
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 12
- 239000002157 polynucleotide Substances 0.000 description 12
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 7
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 7
- 102000048776 human CD274 Human genes 0.000 description 7
- 102000043396 human ICOS Human genes 0.000 description 7
- 102000048362 human PDCD1 Human genes 0.000 description 7
- 230000008685 targeting Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517309P | 2017-06-09 | 2017-06-09 | |
| US62/517,309 | 2017-06-09 | ||
| US201862666278P | 2018-05-03 | 2018-05-03 | |
| US62/666,278 | 2018-05-03 | ||
| PCT/IB2018/054167 WO2018225033A1 (en) | 2017-06-09 | 2018-06-08 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522555A JP2020522555A (ja) | 2020-07-30 |
| JP2020522555A5 true JP2020522555A5 (enExample) | 2021-07-26 |
Family
ID=62873504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567709A Pending JP2020522555A (ja) | 2017-06-09 | 2018-06-08 | 組み合わせ療法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3634483A1 (enExample) |
| JP (1) | JP2020522555A (enExample) |
| CN (1) | CN110869049A (enExample) |
| BR (1) | BR112019025325A2 (enExample) |
| CA (1) | CA3066048A1 (enExample) |
| WO (1) | WO2018225033A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3032897A1 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| WO2021209357A1 (en) * | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
| CN115461362A (zh) * | 2020-04-14 | 2022-12-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN104826106B (zh) * | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| MX373443B (es) | 2011-03-31 | 2020-05-20 | Inst Nat Sante Rech Med | Anticuerpos dirigidos contra icos y usos de los mismos. |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| EP2744830A4 (en) * | 2012-06-21 | 2015-06-17 | Compugen Ltd | LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| EP2892928B1 (en) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| EP3331919A1 (en) * | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
-
2018
- 2018-06-08 CA CA3066048A patent/CA3066048A1/en active Pending
- 2018-06-08 BR BR112019025325-4A patent/BR112019025325A2/pt not_active IP Right Cessation
- 2018-06-08 EP EP18739638.7A patent/EP3634483A1/en not_active Withdrawn
- 2018-06-08 WO PCT/IB2018/054167 patent/WO2018225033A1/en not_active Ceased
- 2018-06-08 JP JP2019567709A patent/JP2020522555A/ja active Pending
- 2018-06-08 CN CN201880044500.1A patent/CN110869049A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6283665B2 (ja) | Ｇｄ２陽性癌を治療するための方法 | |
| JP2017537892A5 (enExample) | ||
| US10485775B2 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP2017537090A5 (enExample) | ||
| US20170354623A1 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| JP2020529421A (ja) | がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ | |
| JP2017533912A5 (enExample) | ||
| JP2016525117A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| KR20230165876A (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| US10973834B2 (en) | EP4 inhibitors and use thereof | |
| Nguyen et al. | A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer | |
| CA2949327A1 (en) | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers | |
| JP7374765B2 (ja) | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 | |
| Gameiro et al. | Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| JP2019524706A5 (enExample) | ||
| JP2022513350A5 (enExample) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| US20220387529A1 (en) | Treatment for primary and metastatic cancer | |
| JP7854724B2 (ja) | 医薬物組合せ及びその使用 | |
| Cimino et al. | Safety considerations with new treatment regimens for anal cancer | |
| JP2024511106A (ja) | Ｐｄ－１阻害剤を投与することにより免疫抑制または免疫不全患者におけるがんを処置する方法 | |
| US20210214442A1 (en) | Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination | |
| CA3170207C (en) | Methods of treating cancer pain by administering a pd-1 inhibitor |